Skip to content

Simulations Plus SLP Commercialization — Revenue

Similar metrics at other companies

Huron Consulting Group logo
HURNCommercial — Revenue
$92.97M+22.6%
Envela logo
ELACommercial — Revenue
$16.59M+44.4%
Ionis Pharmaceuticals logo
IONSCommercial — Revenue
$107.81M+41.5%
Veeva Systems logo
VEEVCommercial Solutions — Total revenues
$337.87M+10.6%
Griffon logo
GFFCommercial — Revenue
$170.63M+1.3%
Palantir Technologies Inc. logo
PLTRCommercial — Revenue
$774.17M+95.1%

Other financials

Income statement

See full
Revenue$24.3M+8.3%
Gross profit$16.1M+23.0%
Operating income$5.6M+108%
Net income$4.5M+47.5%
EPS (diluted)$0.22+46.7%

Balance sheet

See full
Cash & equivalents$25.7M+134%
Total debt$508.0K-36.2%
Total equity$133.8M-29.4%
Total assets$146.5M-27.3%

Cash flow

See full
Operating cash flow$6.4M+13.1%
CapEx$46.0K-30.3%
Free cash flow$6.4M+13.6%

Valuation

See full
Market cap$366.73M+5.2%
Enterprise value$341.51M+6.0%
P/S4.6×+0.2×

Profitability

See full
Gross margin62%+6.7pp
Operating margin-84.3%
Net margin-78%-87.2pp
FCF margin29.5%+14.9pp

Returns & leverage

See full
Return on equity-38.8%-42.8pp
Debt / equity0.0×
Current ratio5.5×+1.1×

Where this comes from

Reported directly by Simulations Plus in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Simulations Plus’s 10-Q, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Simulations Plus's commercialization — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Simulations Plus's commercialization — revenue?
Simulations Plus (SLP) reported commercialization — revenue of $2.28M in Q4 2025.
What does commercialization — revenue mean?
This metric represents the total revenue generated from the commercialization segment, which encompasses the sale of software products and associated consulting services for pharmaceutical research. It serves as a key indicator of the company's ability to monetize its intellectual property and research tools within the life sciences market. Tracking this revenue stream helps investors assess the growth trajectory and market adoption of the company's core software offerings.